ABSTRACT
Objective: To demonstrate the time between the diagnosis of the disease, the result of the immunohistochemical panel and the beginning of specialized treatment in patients diagnosed with breast cancer seen at the Foundation Center of Oncology of the State of Amazonas, from June to November 2018 and in the same period of 2019. Methods: The study was part retrospective, based on data from medical records, and part prospective, based on data from patients, and we evaluated the time between diagnosis from the immunohistochemical panel and the beginning of specialized treatment in breast cancer patients. Results: 170 patients diagnosed with breast cancer were included, 71 from June to November 2018 and 99 breast cancer patients seen from June to November 2019. The median time between diagnosis and immunohistochemistry results of all patients was 36 days, and comparing the two groups of patients, it was observed that for half of the 2018 patients, the time was less than 105 days, while for half of the 2019 patients, it was less than 27 days. If the times between the result of the immunohistochemical panel and the start of personalized treatment in both groups were compared, it was seen that the median time until the start of treatment was longer for patients in 2018, 94.5 days versus 79 days for patients in 2019. Conclusion: There was a decrease in the time between the diagnosis and the result of the molecular panel in 2019 compared to 2018. Achieving this result more quickly provided the choice of personalized treatment for each patient, having an important impact on survival in that population.
ABSTRACT
Introdução: A avaliação da qualidade de vida é importante para uma abordagem mais humana e abrangente. Métodos: Trata-se de um estudo observacional transversal descritivo com abordagem quantitativa que avaliou a qualidade de vida em mulheres submetidas à reconstrução mamária imediata após a mastectomia, no período de janeiro a junho de 2015, na Fundação Centro de Controle de Oncologia do Amazonas. O instrumento de avaliação foi o questionário WHOQOL-bref, seguindo a sintaxe do Grupo WHOQOL. Resultados: Foram avaliadas 22 pacientes, em relação ao perfil sócio demográfico, a faixa etária predominante foi de 45 a 49 anos, o ensino médio foi o mais frequente no estudo (63,64%) e em relação a procedência 90,91% das pacientes foram de Manaus, quanto a estado civil 72,73% eram casadas. Na avaliação através do questionário, a autoavaliação de qualidade de vida foi definida como boa em 41%, o domínio físico apresentou o maior comprometimento, enquanto o domínio de relações sociais foi o menos afetado. Conclusão: A avaliação da qualidade de vida deve ser parte primordial na escolha do tratamento do câncer de mama.
Introduction: The assessment of the quality of life is considered important for a more humanistic and comprehensive treatment approach. Methods: This is a descriptive cross-sectional observational study using a quantitative approach. The quality of life of women undergoing immediate breast reconstruction after mastectomy at the Amazonas Oncology Control Center Foundation (Centro de Controle de Oncologia do Amazonas) from January to June 2015 was assessed. The assessment instrument used was the WHOQOL-BREF questionnaire, following the syntax of the WHOQOL Group. Results: The sociodemographic profiles of 22 patients were evaluated. The predominant age group was 4549 years, the predominant educational level was high school (63.64%), 90.91% of the patients were from Manaus, and 72.73% were married. A total of 41% of the respondents defined their quality of life as good in the questionnaire, with the physical domain being the most affected and the social relationships domain being the less affected. Conclusion: The assessment of the quality of life should be prioritized in the choice of treatment for breast cancer.v